Literature DB >> 2831436

Human colon cell line HT-29: characterisation of 1,25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone.

A Brehier1, M Thomasset.   

Abstract

The human colon carcinoma cell line HT-29 differentiates into functional enterocytes upon replacement of glucose by galactose in the culture medium. Since the differentiation of other types of cells is associated with the modulation of 1,25-dihydroxycholecalciferol (1,25(OH)2D3) receptor concentrations and since enterocytes are classical target cells for 1,25(OH)2D3 we have examined the HT-29 cells to determine whether the differentiated and undifferentiated stages could be directly linked to the presence of 1,25(OH)2D3 receptors. HT-29 cells were grown in Dulbecco's modified medium containing 10% fetal calf serum (FCS) and glucose or galactose. Cell differentiation was assessed by measuring the brush border hydrolase, maltase. 1,25(OH)2D3 receptors were studied in the cells after 48 h without FCS. Nuclear uptake was measured in intact dispersed cells and the receptor protein was further characterized by vitamin D metabolite binding specificity, sucrose density gradient analysis and binding to DNA-cellulose. Maltase activity was 5-fold greater in differentiated HT-29 cells than in undifferentiated cells. Scatchard analysis showed a highly specific saturable (9500 sites per cell) high affinity (2 x 10(-10) M), binding of 1,25(OH)2D3 in undifferentiated cells. This receptor-like protein sedimented at 3.3S, bound to and eluted from DNA-cellulose and had all the characteristics of a 1,25(OH)2D3 receptor. No specific binding was detected in differentiated HT-29 cells. The presence of 1,25(OH)2D3 receptors in undifferentiated HT-29 cells implies that these cells are targets for vitamin D. The maltase activity increased significantly when undifferentiated cells were exposed to 1,25(OH)2D3 for 5-6 days, indicating that the hormone can promote differentiation of HT-29 cells. These results demonstrate that HT-29 cells can provide a new model for studying steroid receptor regulation and cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831436     DOI: 10.1016/0022-4731(88)90275-0

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  11 in total

1.  Cholecalciferol or 25-hydroxycholecalciferol neither prevents nor treats adenomas in a rat model of familial colon cancer.

Authors:  Amy A Irving; Lori A Plum; William J Blaser; Madeline R Ford; Chao Weng; Linda Clipson; Hector F DeLuca; William F Dove
Journal:  J Nutr       Date:  2014-12-24       Impact factor: 4.798

Review 2.  Cellular and molecular effects of vitamin D on carcinogenesis.

Authors:  JoEllen Welsh
Journal:  Arch Biochem Biophys       Date:  2011-11-09       Impact factor: 4.013

3.  1,25(OH)2 vitamin D3 stimulates membrane phosphoinositide turnover, activates protein kinase C, and increases cytosolic calcium in rat colonic epithelium.

Authors:  R K Wali; C L Baum; M D Sitrin; T A Brasitus
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

4.  Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line.

Authors:  M G Thomas; S Tebbutt; R C Williamson
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

5.  Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis.

Authors:  M G Thomas; K P Nugent; A Forbes; R C Williamson
Journal:  Gut       Date:  1994-12       Impact factor: 23.059

6.  Luminal and humoral influences on human rectal epithelial cytokinetics.

Authors:  M G Thomas
Journal:  Ann R Coll Surg Engl       Date:  1995-03       Impact factor: 1.891

7.  1,25-Dihydroxyvitamin D3 and retinoid X receptor expression in human colorectal neoplasms.

Authors:  K F Kane; M J Langman; G R Williams
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

Review 8.  Melanoma and vitamin D.

Authors:  Sinead Field; Julia A Newton-Bishop
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

9.  A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer.

Authors:  T R J Evans; K W Colston; F J Lofts; D Cunningham; D A Anthoney; H Gogas; J S de Bono; K J Hamberg; T Skov; J L Mansi
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

10.  A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.

Authors:  T Gulliford; J English; K W Colston; P Menday; S Moller; R C Coombes
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.